CA1131631A
(en)
*
|
1979-06-20 |
1982-09-14 |
Madhukar S. Chodnekar |
Quinazoline derivatives and pharmaceutical preparations
|
US4818273A
(en)
*
|
1983-11-14 |
1989-04-04 |
The Dow Chemical Company |
Substituted 1,2,4-triazolo[1,5-a]pyrimidine-2-sulfonamides, compositions containing them, and their utility as herbicides
|
US4837239A
(en)
*
|
1985-08-23 |
1989-06-06 |
Syntex (U.S.A.) Inc. |
Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
|
US4761416A
(en)
*
|
1986-07-25 |
1988-08-02 |
Syntex (U.S.A.) Inc. |
N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
|
US4739056A
(en)
*
|
1986-11-26 |
1988-04-19 |
Syntex (U.S.A.) Inc. |
N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
|
JPH05271200A
(ja)
*
|
1991-05-22 |
1993-10-19 |
Egyt Gyogyszervegyeszeti Gyar |
6,7−ジクロロ−1,5−ジヒドロ−イミダゾ〔2,1−b〕キナゾリン−2〔3H〕−オンの製造方法
|
US5391737A
(en)
*
|
1991-05-22 |
1995-02-21 |
Egis Gyogyszergyar |
Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one
|
US5696159A
(en)
*
|
1994-08-03 |
1997-12-09 |
Cell Pathways, Inc. |
Lactone compounds for treating patients with precancerous lesions
|
US5776962A
(en)
*
|
1994-08-03 |
1998-07-07 |
Cell Pathways, Inc. |
Lactone compounds for treating patient with precancerous lesions
|
US6046206A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
|
US6060477A
(en)
*
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
US5874440A
(en)
*
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
US6046216A
(en)
*
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
CA2171073A1
(en)
*
|
1995-12-04 |
1997-06-05 |
Philip C. Lang |
Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
|
US5858694A
(en)
*
|
1997-05-30 |
1999-01-12 |
Cell Pathways, Inc. |
Method for identifying compounds for inhibition of cancerous lesions
|
CA2238283C
(en)
*
|
1997-05-30 |
2002-08-20 |
Cell Pathways, Inc. |
Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
|
US5852035A
(en)
*
|
1997-12-12 |
1998-12-22 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
US6410584B1
(en)
*
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
US5942520A
(en)
*
|
1998-01-27 |
1999-08-24 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
|
US5990117A
(en)
*
|
1998-04-15 |
1999-11-23 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
|
US6180629B1
(en)
|
1998-08-14 |
2001-01-30 |
Cell Pathways, Inc. |
[4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
|
US6124303A
(en)
*
|
1998-09-11 |
2000-09-26 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
US6130053A
(en)
*
|
1999-08-03 |
2000-10-10 |
Cell Pathways, Inc. |
Method for selecting compounds for inhibition of neoplastic lesions
|
US6200771B1
(en)
|
1998-10-15 |
2001-03-13 |
Cell Pathways, Inc. |
Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
US6369092B1
(en)
|
1998-11-23 |
2002-04-09 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted benzimidazole derivatives
|
US6077842A
(en)
*
|
1998-11-24 |
2000-06-20 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
|
US6034099A
(en)
*
|
1998-11-24 |
2000-03-07 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
US6025394A
(en)
|
1999-01-29 |
2000-02-15 |
Cell Pathways, Inc. |
Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
|
US6020379A
(en)
*
|
1999-02-19 |
2000-02-01 |
Cell Pathways, Inc. |
Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
|
WO2001021259A2
(en)
*
|
1999-09-21 |
2001-03-29 |
Emory University |
Use and compositions for treating platelet-related disorders using anagrelide
|
US6194420B1
(en)
*
|
1999-11-30 |
2001-02-27 |
Roberts Laboratories Inc. |
2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
|
US6555547B1
(en)
|
2000-02-28 |
2003-04-29 |
Cell Pathways, Inc. |
Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
|
US6569638B1
(en)
|
2000-03-03 |
2003-05-27 |
Cell Pathways, Inc |
Method for screening compounds for the treatment of neoplasia
|
US6388073B1
(en)
|
2000-07-26 |
2002-05-14 |
Shire Us Inc. |
Method for the manufacture of anagrelide
|
DE10301105B4
(de)
*
|
2003-01-09 |
2005-11-24 |
Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh |
Verwendung von 2-Amino-2H-chinazolin-Derivaten zur Behandlung von myeloproliferativen Erkrankungen, Bluthochdruck und Bronchodilation
|
KR20050111317A
(ko)
*
|
2003-01-23 |
2005-11-24 |
샤이어 홀딩스 아게 |
혈소판혈병의 치료를 위한 제형 및 방법
|
AT412873B
(de)
*
|
2004-02-20 |
2005-08-25 |
Aop Orphan Pharmaceuticals Ag |
Verfahren zur herstellung von anagrelid hydrochlorid
|
US20060030574A1
(en)
*
|
2004-08-04 |
2006-02-09 |
Shire Holdings Ag |
Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
|
US7700608B2
(en)
*
|
2004-08-04 |
2010-04-20 |
Shire Holdings Ag |
Quinazoline derivatives and their use in the treatment of thrombocythemia
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
WO2007025177A2
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
EP2377530A3
(en)
|
2005-10-21 |
2012-06-20 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US20070244143A1
(en)
*
|
2006-03-08 |
2007-10-18 |
Braincells, Inc |
Modulation of neurogenesis by nootropic agents
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
US7678808B2
(en)
|
2006-05-09 |
2010-03-16 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
EP2377531A2
(en)
|
2006-05-09 |
2011-10-19 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
MX2009002496A
(es)
*
|
2006-09-08 |
2009-07-10 |
Braincells Inc |
Combinaciones que contienen un derivado de 4-acilaminopiridina.
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
EP2066355A2
(en)
*
|
2006-09-19 |
2009-06-10 |
Braincells, Inc. |
Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
|
GB0623749D0
(en)
*
|
2006-11-28 |
2007-01-10 |
Shire Llc |
Substituted quinazolines
|
US7910597B2
(en)
*
|
2006-11-28 |
2011-03-22 |
Shire Llc |
Substituted quinazolines
|
US8304420B2
(en)
*
|
2006-11-28 |
2012-11-06 |
Shire Llc |
Substituted quinazolines for reducing platelet count
|
AR064106A1
(es)
*
|
2006-12-05 |
2009-03-11 |
Bayer Schering Pharma Ag |
Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
|
US8133996B2
(en)
*
|
2007-02-06 |
2012-03-13 |
Cipla Limited |
Process for the preparation of ethyl-N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride
|
CN101463035A
(zh)
*
|
2007-12-19 |
2009-06-24 |
华生制药私人有限公司 |
生产盐酸阿那格雷一水合物的改进方法
|
GB0808967D0
(en)
*
|
2008-05-16 |
2008-06-25 |
Shire Llc |
Substitute quinazolines
|
GB0808953D0
(en)
|
2008-05-16 |
2008-06-25 |
Shire Llc |
substituted quinazolines
|
GB0808944D0
(en)
*
|
2008-05-16 |
2008-06-25 |
Shire Llc |
Substituted quinazolines
|
GB0808947D0
(en)
*
|
2008-05-16 |
2008-06-25 |
Shire Llc |
Substituted quinazolines
|
GB0808968D0
(en)
*
|
2008-05-16 |
2008-06-25 |
Shire Llc |
Substitute quinazolines
|
GB0808951D0
(en)
*
|
2008-05-16 |
2008-06-25 |
Shire Llc |
Substituted quinazolines
|
GB2460915B
(en)
*
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
GB201004491D0
(en)
|
2010-03-18 |
2010-05-05 |
Shire Llc |
Quinazoline analogues
|
GB201017783D0
(en)
|
2010-10-21 |
2010-12-01 |
Shire Llc |
Process for the preparation of anagrelide and analogues thereof
|
EP2804603A1
(en)
|
2012-01-10 |
2014-11-26 |
President and Fellows of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
ES2794917T3
(es)
|
2013-01-18 |
2020-11-19 |
Synthon Bv |
Forma cristalina II de clorhidrato de anagrelida monohidratado
|
EP2981537B1
(en)
*
|
2013-03-14 |
2017-05-10 |
Synthon B.V. |
Process for making anagrelide
|
EP3013831A1
(en)
|
2013-06-28 |
2016-05-04 |
Synthon BV |
Process for making anagrelide
|
CN106854162A
(zh)
*
|
2016-12-13 |
2017-06-16 |
浙江海正化工股份有限公司 |
一种2,3‑二氯‑6‑硝基苯胺及其制备方法
|
CN107903217B
(zh)
*
|
2017-11-16 |
2021-11-23 |
湖北省宏源药业科技股份有限公司 |
一种阿那格雷杂质b的制备方法
|
CA3113025A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
CA3113353A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|